Abstract
Abstract
Background
Major transition in tuberculosis (TB) epidemiology is taking place in many European countries including Finland. Monitoring treatment outcome of TB cases is important for identifying gaps in the national TB control program, in order to strengthen the system. The aim of the study was to identify potential risk factors for non-successful TB treatment outcomes, with a particular focus on the impact of comorbidities. We also evaluated the treatment outcome monitoring system.
Methods
All notified microbiologically confirmed pulmonary TB cases in Finland in 2007–2014 were included, except multi-drug resistant (MDR) cases. Nationwide register data were retrieved from: Infectious Diseases Register, Population Register, Cause of Death Register and Hospital Discharge Register. Non-successful outcomes were divided into three groups: death, unsatisfactory outcomes and non-defined outcomes. Logistic regression analyses were used to identify risk factors for non-successful outcomes.
Results
Treatment outcomes were notified for 98.6% of study cases (n = 1396/1416). Treatment success rate was 75%. The main reason for non-successful outcome was death (16%), whereas outcomes failed and lost to follow-up were rare (1% together). In a multivariable model, risk factors for death as outcome were increasing age, male gender and Charlson comorbidity index ≥1, for unsatisfactory outcomes non-MDR drug resistance and TB registered in the first study period, and for non-defined outcomes non-MDR drug resistance. Among 50 cases with unsatisfactory outcomes, we observed false outcome allocations in eight (16%), and > 2% of the cases transferred to another country or disappeared before or during treatment.
Conclusions
With a high proportion of older population among tuberculosis cases, death is a common treatment outcome in Finland. Comorbidity is an important factor to be incorporated when interpreting and comparing outcome rates. There was a considerable inconsistency in outcome allocation in the monitoring system, which implies that there is need to review the guidelines and provide further training for outcome assessment.
Funder
Tuberculosis Foundation of Tampere
Publisher
Springer Science and Business Media LLC
Subject
Public Health, Environmental and Occupational Health
Reference36 articles.
1. European Centre for Disease Prevention and Control, World Health Organization Regional Office for Europe. Tuberculosis Surveillance and Monitoring in Europe 2019, 2019. https://www.ecdc.europa.eu/sites/default/files/documents/tuberculosis-surveillance-monitoring-Europe-2019-20_Mar_2019.pdf. Accessed 17 January 2020.
2. World Health Organization. Definitions and Reporting Framework for Tuberculosis, 2013 revision updated December 2014. http://www.who.int/tb/publications/definitions/en/. Accessed 17 January 2020.
3. Karo B, Hauer B, Hollo V, van der Warf MJ, Fiebig L, Haas W. Tuberculosis treatment outcome in the European Union and European economic area: an analysis of surveillance data from 2002–2011. Eurosurveillance. 2015;20:30087. https://doi.org/10.2807/1560-7917.ES.2015.20.49.30087.
4. World Health Organization. The End TB Strategy. https://www.who.int/tb/post2015_strategy/en/. Accessed 23 October 2019.
5. Vasankari T, Kokki M, Holmstrom P, Liippo K, Sarna S, Ruutu P. Surveillance report: great diversity of tuberculosis treatment in Finland. Eurosurveillance. 2007;12:17–21.
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献